Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
27 Agosto 2024 - 10:05PM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
radiopharma company focused on developing innovative treatments for
cancer patients, today announced that it received notice from The
Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance
with the minimum bid price requirement under Nasdaq Listing Rule
5550(a)(2) as a result of the closing bid price of the Company’s
common stock being $1.00 per share or greater for 10 consecutive
trading sessions. The Company is now compliant with the minimum bid
price listing standard for continued Nasdaq listing.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage radiopharmaceutical
company focused on developing innovative treatments for cancer
patients, including Phase 1-stage MNPR-101-Zr for imaging advanced
cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage
MNPR-101-Ac225 for the treatment of advanced cancers, as well as
early development stage programs against solid cancers. For more
information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.Investor
RelationsKarthik RadhakrishnanChief Financial
Officerkarthik@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
Grafico Azioni Monopar Therapeutics (NASDAQ:MNPR)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Monopar Therapeutics (NASDAQ:MNPR)
Storico
Da Nov 2023 a Nov 2024
